Ongoing Clinical Trials for Pancreatic Neuroendocrine Tumour Metastatic

Currently, there are 2 ongoing clinical trials focused on pancreatic neuroendocrine tumour metastatic. These trials are investigating advanced imaging techniques to better understand tumor behavior and predict disease progression. Both studies are being conducted in Denmark and use specialized scanning methods to evaluate how neuroendocrine tumors develop and respond over time.

Clinical trial locations

• Denmark
  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas
  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

This trial focuses on developing new ways to predict how long patients might remain stable without their disease worsening. The study uses two different imaging substances combined with PET/CT scanning to create detailed pictures of tumors and assess their characteristics.

Main inclusion criteria: Participants must be between 18 and 65 years old with a confirmed diagnosis of gastro-pancreatic neuroendocrine neoplasm through tissue examination or have tumor spread suggesting this type of cancer. They must be able to care for themselves with a WHO Performance status of 0-2, and be able to read and understand the patient information to provide informed consent. Both men and women can participate.

Main exclusion criteria: People cannot participate if they are younger than 18 or older than 65 years, are unable to undergo PET/CT scanning, have known allergies to the imaging agents, are pregnant or breastfeeding, or cannot provide informed consent. Other exclusions include participation in another clinical trial within the past 30 days, severe claustrophobia, metal implants that could interfere with imaging, inability to lie still for 30-45 minutes, serious medical conditions, or a history of other active cancers in the past 5 years.

Trial focus: The study aims to develop predictive models for disease progression by analyzing measurements from combined scans using both imaging substances. Participants will undergo two separate imaging procedures on the same day, followed by health monitoring until December 31, 2026. The scan results will help determine tumor characteristics and suitability for additional treatments in the future.

Investigational drugs: The trial uses 64Cu-DOTATATE, a radioactive tracer that binds to receptors commonly found on neuroendocrine tumors to help visualize their location throughout the body. It also uses 18F-FDG (fluorodeoxyglucose), which shows areas in the body that use a lot of glucose, helping doctors see how active tumor cells are. Both tracers are given as single injections into a vein and provide complementary information about the tumors.

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

This trial tests a new imaging method that combines two different techniques to better understand how tumors use energy. The study includes patients with various types of cancer, including neuroendocrine neoplasms. Both imaging procedures are performed simultaneously using a combined PET/MR scanner.

Main inclusion criteria: Participants must be adults aged 18 years or older. Both men and women can participate. They must have a confirmed diagnosis of breast cancer, neuroendocrine neoplasm, lymphoma, or sarcoma. The tumor must be at least 1.5 centimeters in size, and participants must be able to give informed consent.

Main exclusion criteria: People cannot participate if they are under 18 or over 65 years old, unable to lie still in the scanner for up to 60 minutes, have claustrophobia, have metal implants not compatible with MRI, are pregnant or breastfeeding, or have severe kidney dysfunction. Other exclusions include known allergies to imaging substances, participation in other experimental drug studies within 30 days, inability to provide informed consent, uncontrolled medical conditions, weight over 180 kg, or blood glucose levels above 200 mg/dL at the time of imaging.

Trial focus: The study determines whether it is possible to perform both imaging methods at the same time to better understand tumor energy metabolism. Participants receive two injectable substances and undergo a single imaging session in a combined PET/MR scanner. The research helps doctors understand how tumors process different nutrients and may lead to improved ways of detecting and monitoring cancer.

Investigational drugs: The trial uses Hyperpolarized [1-13C]Pyruvate, an imaging agent that helps doctors see how cancer cells process nutrients differently from normal cells by visualizing metabolic processes in real-time. It also uses 18F-FDG, a radioactive form of glucose that accumulates in cancer cells because they typically consume more glucose than healthy cells. Both substances are injected intravenously and provide detailed information about tumor metabolism using complementary imaging techniques.

Summary

Both ongoing clinical trials for pancreatic neuroendocrine tumour metastatic are being conducted in Denmark and focus on advanced imaging techniques rather than testing new treatments. The trials share a common goal of better understanding tumor behavior and metabolism through specialized scanning methods. Notably, both studies use 18F-FDG as one of their imaging agents, demonstrating the importance of glucose metabolism assessment in neuroendocrine tumors. The first trial specifically targets gastro-pancreatic neuroendocrine neoplasms with the goal of predicting disease progression, while the second trial includes neuroendocrine tumors among several cancer types to study energy metabolism. These trials may help improve future cancer detection and monitoring methods, though they do not offer therapeutic interventions themselves.